CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC

Amanda Herrmann, MD, discusses findings from the 5-year update from CheckMate-9LA investigating nivolumab, ipilimumab, and chemotherapy in patients with metastatic NSCLC.

EP: 1.Introduction of the UCSD vs City of Hope Face-Off

EP: 2.Advanced ALK-Rearranged NSCLC

EP: 3.Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN

Now Viewing

EP: 4.CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC

EP: 5.Where Does the POSEIDON Regimen Fit in the NSCLC Treatment Landscape?

EP: 6.A Case of Metastatic ROS1 Fusion-Positive NSCLC

EP: 7.Patient Profile: EGFRm Post-Osimertinib

EP: 8.Patient Case: PD-L1 Negative NSCLC

EP: 9.KRAS Patient Case

EP: 10.Neoadjuvant Chemoimmunotherapy for Resectable NSCLC

EP: 11.Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?

EP: 12.Treatment Options for Patients with EGFRm: EGFR TKI + Chemotherapy

EP: 13.Treatment Options for Patients with EGFRm: EGFR TKI

EP: 14.Face-Off: Award Ceremony

Recent Videos